Blog
RSS FeedPosted by Michael Wonder on 10 Mar 2023
Alberta’s import of children’s medication to cost taxpayers $80 million
9 March 2023 - Alberta taxpayers are on the hook for $80 million, after Health Minister Jason Copping finally revealed ...
Posted by Michael Wonder on 09 Mar 2023
CADTH recommends reimbursement for BioCryst’s Orladeyo (berotralstat) for the routine prevention of attacks in hereditary angioedema patients in Canada
8 March 2023 - BioCryst Pharmaceuticals today announced that the CADTH Canadian Drug Expert Committee has issued a positive recommendation ...
Posted by Michael Wonder on 03 Mar 2023
Health minister disputes claim he sided with big pharma, interfered with drug price consultations
1 March 2023 - Review board 'will never be subjected to political interference,' Duclos said. ...
Posted by Michael Wonder on 01 Mar 2023
The drug prices review board was once a solution. It’s now a problem.
1 March 2023 - Anti-drug company activists are repeating ill-informed myths about controlling drug prices in Canada. ...
Posted by Michael Wonder on 24 Feb 2023
Member of Canada’s drug pricing regulator quits over ‘lack of support’ for medicine cost reforms
23 February 2023 - A member of the Patented Medicine Prices Review Board, Canada’s drug pricing regulator, has resigned over ...
Posted by Michael Wonder on 07 Feb 2023
Valeo Pharma obtains public reimbursement for Onstryv in Quebec
7 February 2023 - Quebec public reimbursement coverage to facilitate and expand medication access for Parkinson’s patients in Quebec. ...
Posted by Michael Wonder on 02 Feb 2023
Medexus secures public reimbursement for Cuvposa in Quebec
1 February 2023 - Medexus Pharmaceuticals wishes to inform investors that the company has reached an agreement with the provincial government ...
Posted by Michael Wonder on 19 Jan 2023
Radicava (edarvarone) oral suspension receives positive recommendation from CADTH for the treatment of patients with ALS
18 January 2023 - Mitsubishi Tanabe Pharma Canada is pleased to announce a positive recommendation from the CADTH Canadian Drug Expert ...
Posted by Michael Wonder on 17 Jan 2023
Innovative Medicines Canada proposes framework for innovative agreements for drug reimbursement
16 January 2023 - Pharmaceutical manufacturers in Canada often enter into product listing agreements, particularly with public payers, to facilitate their ...
Posted by Michael Wonder on 21 Dec 2022
Ontario expanding safe use of biosimilars
20 December 2022 - Transitioning to biosimilars will allow province to invest in and improve access to medicines. ...
Posted by Michael Wonder on 20 Dec 2022
Radicava (edaravone) oral suspension receives positive recommendation from INESSS for the treatment of patients with ALS
19 December 2022 - Mitsubishi Tanabe Pharma Canada is pleased to announce a positive recommendation from the Institut national d'excellence en ...
Posted by Michael Wonder on 03 Dec 2022
AbbVie announces provincial reimbursement for Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis and psoriatic arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan
1 December 2022 - AbbVie today announced that Rinvoq is now listed as a special authorisation medication or exception medication status ...
Posted by Michael Wonder on 01 Dec 2022
Livtencity (maribavir) receives positive CADTH recommendation for adults with post-transplant cytomegalovirus infection
1 December 2022 - The conditions for the positive recommendation is supported by the findings of the Phase 3 SOLSTICE ...
Posted by Michael Wonder on 11 Nov 2022
CADTH launches consultation on real world evidence reporting guidance
10 November 2022 - Today, CADTH, on behalf of the Real World Evidence Steering Committee, launched a public consultation to ...
Posted by Michael Wonder on 11 Nov 2022
Implementation of the Patented Medicine Prices Review Board's proposed Guidelines will harm Canadian patients
10 November 2022 - Innovative Medicines Canada is calling on Health Canada to direct the Patented Medicine Prices Review Board (PMPRB) ...